Noninvasive Evaluation of Fibrosis and Portal Hypertension in Primary Biliary Cholangitis.

Clin Liver Dis

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, French network for rare liver diseases FILFOIE, European Reference Network ERN RARE-LIVER, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Inserm UMR_S938, Saint-Antoine Research Center (CRSA), Sorbonne University, 184 rue du Faubourg Saint-Antoine, Paris 75571 Cedex 12, France. Electronic address:

Published: November 2022

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that, if left untreated or insufficiently treated, inexorably progresses toward cirrhosis and its potentially fatal complications. Alongside with the biochemical response to ursodeoxycholic acid therapy, advanced liver fibrosis and portal hypertension (PH) were shown to be major prognostic determinants in PBC. Therefore, one of the goals of noninvasive PBC evaluation should be to early diagnose compensated advanced disease and/or clinically significant PH. In this article, the main methods of noninvasive assessment of liver fibrosis and PH in PBC, and their clinical relevance, will be reviewed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cld.2022.06.010DOI Listing

Publication Analysis

Top Keywords

fibrosis portal
8
portal hypertension
8
primary biliary
8
biliary cholangitis
8
liver fibrosis
8
noninvasive evaluation
4
evaluation fibrosis
4
hypertension primary
4
cholangitis primary
4
pbc
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!